Physicians' Academy for Cardiovascular Education

Practical management of cardiovascular risk: Lessons from latest diabetes trials

Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

10' education - June 25, 2018 - Prof. Lars Rydén, MD - Karolinska Institute Stockholm, Sweden - Online CME

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Video navigation menu

  • Incretin-based glucose lowering 00:34
  • Short-acting GLP-1 RA in T2DM: results from outcome trials 03:01
  • GLP-1 RA- human analogues: results from outcome trials 05:37
  • LEADER / SUSTAIN 6 study details 07:00
  • Reasons for different outcomes between GLP-1 RA trials 16:26


Professor Lars Rydén, MD - Senior Professor of Cardiology, Karolinska Institute, Stockholm, Sweden


This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.


Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.

Also view: Diabetes: How to reduce risk from a cardiovascular perspective? by prof Rick Grobbee View and download presentation slides


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: